Logan Capital Management Inc. Trims Holdings in Jazz Pharmaceuticals PLC $JAZZ

Logan Capital Management Inc. cut its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 59.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,094 shares of the specialty pharmaceutical company’s stock after selling 1,594 shares during the quarter. Logan Capital Management Inc.’s holdings in Jazz Pharmaceuticals were worth $116,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Hurley Capital LLC purchased a new stake in shares of Jazz Pharmaceuticals in the 1st quarter worth about $25,000. Spire Wealth Management grew its position in shares of Jazz Pharmaceuticals by 137.6% in the 1st quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company’s stock worth $35,000 after buying an additional 161 shares during the period. Picton Mahoney Asset Management grew its position in shares of Jazz Pharmaceuticals by 2,445.5% in the 1st quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock worth $34,000 after buying an additional 269 shares during the period. SVB Wealth LLC purchased a new stake in shares of Jazz Pharmaceuticals in the 1st quarter worth about $36,000. Finally, Geneos Wealth Management Inc. grew its position in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 137 shares during the period. 89.14% of the stock is owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Price Performance

JAZZ opened at $138.13 on Wednesday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. The stock has a market capitalization of $8.38 billion, a P/E ratio of -20.52, a P/E/G ratio of 8.89 and a beta of 0.28. The company’s 50-day simple moving average is $131.25 and its two-hundred day simple moving average is $117.51. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The company had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. Jazz Pharmaceuticals’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Morgan Stanley set a $183.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday. Zacks Research upgraded shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. Truist Financial upped their price target on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a research note on Thursday, August 28th. JPMorgan Chase & Co. dropped their price target on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a research note on Monday. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They issued a “buy” rating and a $152.00 price target on the stock. Fourteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $179.33.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the company’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total transaction of $771,720.00. Following the transaction, the director owned 429,973 shares in the company, valued at approximately $55,303,127.26. This represents a 1.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders have sold 11,500 shares of company stock worth $1,525,280. 4.30% of the stock is currently owned by corporate insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.